Ladenburg Thalmann Upgrades Ardelyx to 'Buy' with $16 Target

Ladenburg Thalmann sees upside in Ardelyx, Inc., setting a $16 price target.

Written by EarningsIQ · Published Jun 16, 2026, 1:01 PM EDT · Updated Jun 16, 2026, 3:00 PM EDT

Key Points

Ladenburg Thalmann upgraded Ardelyx, Inc. (NASDAQ: ARDX) to a 'buy' rating with a $16 price target on June 16, 2026.
Ardelyx shares were trading around $5.69, with a market cap of $1.4 billion and a forward P/E of 11.04.
Insider sales occurred on May 21, 2026, involving several executives, with no insider purchases reported.

Ladenburg Thalmann has upgraded its rating on Ardelyx, Inc. (NASDAQ: ARDX) to 'buy', setting a price target of $16. The announcement was made on June 16, 2026, reflecting confidence in Ardelyx's growth potential. Shares of Ardelyx recently traded at around $5.69.

Analysts Set New Price Targets

Ladenburg Thalmann's analyst Caroline Palomeque assumed coverage with a 'buy' rating, targeting $16 per share. Other analysts have also shown optimism. On February 20, 2026, HC Wainwright & Co. maintained a 'buy' rating with an $18 target. Earlier in January, Wedbush and Citigroup maintained their 'buy' ratings with targets of $19 and $14, respectively. Piper Sandler upgraded the stock to 'buy' with a $16 target on January 9, 2026.

Ardelyx Stock Snapshot

Shares of Ardelyx, Inc. on the NasdaqGM hovered around $5.69. The company has a market capitalization of $1.4 billion and a forward P/E ratio of 11.04. Ardelyx's beta is 0.576, indicating lower volatility compared to the market. The 52-week trading range is between $3.49 and $8.40, with a 50-day moving average of $6.16 and a 200-day moving average of $6.12. The company maintains a current ratio of 3.49 and a quick ratio of 2.93, but holds a debt-to-equity ratio of 157.53.

Insider Buying and Selling at Ardelyx, Inc.

There were several insider transactions on May 21, 2026. President & CEO Michael Raab sold 54,748 shares at an average price of $6.27. Other executives, including Chief Commercial Officer Eric Duane Foster and Chief Patient Officer Laura Williams, also sold shares on the same date.

About Ardelyx, Inc.

Ardelyx, Inc., headquartered in Waltham, Massachusetts, is a biotechnology company specializing in the discovery, development, and commercialization of therapies for unmet medical needs. Notably, it offers IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in chronic kidney disease patients on dialysis. The company was founded in 2007 and is led by CEO Michael G. Raab.

Bottom Line

Ladenburg Thalmann's recent upgrade to a 'buy' rating with a $16 target reflects a positive outlook on Ardelyx, Inc. Investors often track such analyst upgrades for insights into potential stock performance. However, it's important to remember that these ratings are based on past and present data, which may not predict future results.